This study involved subjects with NTG and healthy subjects who were enrolled in the Investigating Glaucoma Progression Study, which is an ongoing prospective study at the Glaucoma Clinic of Seoul National University Bundang Hospital. This study also involved subjects with NAION who visited Seoul National University Bundang Hospital from January 2016 to May 2018. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital and followed the tenets of the Declaration of Helsinki. Written informed consent to participate was obtained from patients with NTG. The charts of patients with NAION were reviewed retrospectively, with informed consent waived by the institutional review board.
Each subject underwent comprehensive ophthalmic examinations, which included assessments of best-corrected visual acuity, Goldmann applanation tonometry, a refraction test, slit-lamp biomicroscopy, gonioscopy, stereo disc photography, red-free fundus photography (Kowa VX-10; Kowa Medicals, Torrance, CA), standard automated perimetry (Humphrey Field Analyzer II 750, 24-2 Swedish interactive threshold algorithm; Carl Zeiss Meditec, Dublin, CA), measurement of circumpapillary RNFL thickness using spectral-domain OCT (Spectralis, Heidelberg Engineering, Heidelberg, Germany), and swept-source OCTA (DRI OCT Triton, Topcon, Tokyo, Japan). Other ophthalmic examinations included measurements of corneal curvature (KR-1800, Topcon), central corneal thickness (Orbscan II, Bausch & Lomb Surgical, Rochester, NY), and axial length (IOLMaster version 5, Carl Zeiss Meditec).
A clinical history was also obtained from each participant, including demographic characteristics and the presence of cold extremities, migraine, and other systemic conditions. Definition of NTG, NAION, and healthy subjects, criteria for inclusion and exclusion, and the measurement of blood pressure and cup-to-disc ratio are described in the
Appendix in the Supplement.
Patients in the NTG group were required to be treatment naïve to rule out the potential effects of IOP and IOP-lowering medications on the ONH VD.
24 IOP was measured and OCTA scans of the ONH performed before the initiation of ocular hypotensive treatment. In each patient with NTG and NAION, either the superotemporal or inferotemporal sector of the eye affected by disease (i.e., RNFL defect with corresponding hemi visual field defect) was defined as the affected sector. NAION subjects were matched 1:1 with patients with NTG based on age and RNFL thicknesses in the superior and inferior quadrants. Healthy subjects were matched for age with NAION and NTG groups. If both eyes were eligible for inclusion, one eye was selected randomly for each patient.